Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positive non-small cell lung cancer.
Lung Cancer
DRUG: TQB2450|DRUG: Anlotinib
Overall response rate （ORR）, Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR), up to approximately 12 months
Progression-free survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to approximately 12 months|Overall survival (OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to approximately 15 months|Disease control rate（DCR）, Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD)., up to approximately 12 months
This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positive non-small cell lung cancer.